TMCnet News
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity now preferred SEATTLE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted significant updates to the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma that further establish highly sensitive minimal (or measurable) residual disease (MRD) assessment as an important tool in myeloma care. For the first time, NCCN Guidelines® include a dedicated page that outlines Principles of MRD Testing, underscoring the importance of MRD testing in modern myeloma management. The new page, MYEL-E, gives clinicians a clearer, more consistent approach to using MRD testing in patients. The update builds on years of clinical evidence demonstrating that MRD negativity is associated with longer progression-free survival and overall survival. By bringing MRD testing recommendations together in one place, the updated guidelines may help support more informed conversations between patients and their care teams about disease status, treatment decisions, and ongoing monitoring. Significant additions to the NCCN MRD recommendations include:
Most importantly, the updated guidelines reflect the growing clinical utility of MRD assessment in helping clinicians evaluate response to therapy and personalize treatment decisions. The guidelines note that MRD negativity and sustained MRD negativity can help guide treatment escalation, de-escalation, and maintenance therapy as part of a shared decision-making process with patients. Conversely, rising MRD positivity may prompt, at a minimum, closer monitoring and clinical evaluation. “The updated NCCN Guidelines represent an important step forward in how we use MRD in multiple myeloma. Greater sensitivity matters, as it is associated with clinical outcomes, and assessing MRD at a sensitivity of 10?6 gives us a more precise understanding of the depth of response,” said Ola Landgren, MD, PhD, director of the Sylvester Myeloma Institute at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine. “Equally important is the recognition that MRD should be followed over time. Sustained MRD negativity is more informative than a single negative result. Incorporating MRD into decisions about treatment duration, including the possibility of discontinuing herapy in selected patients with sustained MRD negativity, moves the field toward a more individualized approach in which we aim not only to achieve deep responses, but also to avoid unnecessary treatment.” “NCCN Guidelines play an important role in advancing the standard of care for patients, particularly by helping community oncologists access and apply the latest guidance,” said Susan Bobulsky, Chief Commercial Officer, MRD, Adaptive Biotechnologies. “The updated myeloma guidelines provide more detailed recommendations for MRD testing timepoints and frequency, helping clinicians incorporate MRD assessment into care throughout the myeloma treatment continuum. These updates underscore clonoSEQ’s established leadership in hematology MRD testing and reflect the continued evolution of the field toward MRD-informed patient care.” The latest NCCN Guidelines can be accessed here. About clonoSEQ clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier. clonoSEQ has been extensively studied in more than 300 peer-reviewed publications. clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request. To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary. About Adaptive Biotechnologies Forward-Looking Statements In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections regarding the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. Note: NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. ADAPTIVE INVESTORS ADAPTIVE MEDIA 
|
